CAR T-Matters, a €1.7 million EU project co-funded by COMPETE 2030 through the European Regional Development Fund (FEDER), brings together partners from the academic,  clinical, and industrial sectors (NOVA FCT, IPO Porto, and Stemmatters, respectively) to develop the first national platform for the production and development of CAR T-cell therapies in Portugal. The project aims to address current gaps in the clinical translation of this type of immunotherapy and strengthen national capacity in advanced cancer therapies.

Researchers from two NOVA FCT research units, UCIBIO and LAQV, are involved in the project. The Glycoimmunology Research Lab at UCIBIO is contributing its expertise in glycobiology, immunology, and chemoinformatics to identify and validate molecules capable of enhancing CAR T-cell function and safety, with Paula Videira leading this work package.

The CAR T-Matters Mid-Project Meeting will take place on 28 May, from 09:45 to 17:30, at the NOVA FCT Library Auditorium, Caparica Campus. Please note that the morning session (09:45–13:00) will be open to all interested participants upon registration, while the afternoon session will be restricted to project consortium members.

Registration details will be shared in the coming days - stay tuned. The indicative registration deadline is 22 May.

Do not miss this opportunity to hear from leading experts and take part in this important meeting.

Below you can find the meeting programme and details of the morning session speakers.